Investigational drugs for nasopharyngeal carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Hong Kong Cancer Registry, Hong Kong Hospital Authority. 2016. Available from: http://www3.ha.org.hk/cancereg/
   Google Scholar
• Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33:3356–3364.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883–1892.
   PubMed Web of Science ®Google Scholar
• Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:451–462.
   PubMed Web of Science ®Google Scholar
• Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22:79–86.
   PubMed Web of Science ®Google Scholar
• Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46:866–871.
   PubMed Web of Science ®Google Scholar
• Zheng H, Dai W, Cheung AK, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-kappaB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113:11283–11288.
   PubMed Web of Science ®Google Scholar
• Li YY, Chung GT, Lui VW, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. Nat Commun. 2017;8:14121.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–2199.
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–2145.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–3473.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189–12202.
   PubMed Web of Science ®Google Scholar
• Bruce JP, Yip K, Bratman SV, et al. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33:3346–3355.
   PubMed Web of Science ®Google Scholar
• Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393–1403.
   PubMed Web of Science ®Google Scholar
• Hsu C, Lee S, Ejadi S, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: interim results from a phase 1b study. ESMO Asia 2015, Singapore. Ann Oncol. 2015;26(suppl 9):Abstract 3150.
   Google Scholar
• Demaria S, Pilones KA, Vanpouille-Box C, et al. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res. 2014;182:170–181.
   PubMed Web of Science ®Google Scholar
• Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23:8942–8949.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105:1898–1904.
   PubMed Web of Science ®Google Scholar
• Li J, Chen QY, He J, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015;4:e976507.
   PubMed Web of Science ®Google Scholar
• Secondino S, Zecca M, Licitra L, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol. 2012;23:435–441.
   PubMed Web of Science ®Google Scholar
• Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014;22:132–139.
   PubMed Web of Science ®Google Scholar
• Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012;72:1116–1125.
   PubMed Web of Science ®Google Scholar
• Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73:1676–1688.
   PubMed Web of Science ®Google Scholar
• Chia WK, Wang WW, Teo M, et al. A phase II study evaluating the safety and efficacy of an adenovirus-{Delta}LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2011;23:997–1005.
   PubMed Web of Science ®Google Scholar
• Hong B, Lui VW, Hashiguchi M, et al. Targeting tumor hypoxia in nasopharyngeal carcinoma. Head Neck. 2011;35:133–145.
   PubMed Web of Science ®Google Scholar
• Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8:2595–2604.
   PubMed Web of Science ®Google Scholar
• Hui EP, Sung FL, Yu BK, et al. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res. 2008;14:7080–7087.
   PubMed Web of Science ®Google Scholar
• Hui EP, Lui VW, Wong CS, et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs. 2010;29:1123–1131.
   PubMed Web of Science ®Google Scholar
• Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 2010;22:1280–1287.
   Web of Science ®Google Scholar
• Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28:21–28.
   PubMed Web of Science ®Google Scholar
• Lim WT, Ng QS, Percy I, et al. Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res. 2011;17:5481–5489.
   PubMed Web of Science ®Google Scholar
• Hui EP, Ma B, Mo F, et al. A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma. ASCO 2015, Chicago. J Clin Oncol. 2015;33(supp):abstr 6031.
   Google Scholar
• Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25:3766–3773.
   PubMed Web of Science ®Google Scholar
• Xue C, Huang Y, Huang PY, et al. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013;24:1055–1061.
   PubMed Web of Science ®Google Scholar
• Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13:172–180.
   PubMed Web of Science ®Google Scholar
• Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–6738.
   PubMed Web of Science ®Google Scholar
• Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs. radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:1188–1198.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356–1364.
   PubMed Web of Science ®Google Scholar
• Walia A, Yang JF, Huang YH, et al. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 2015;1850:2422–2438.
   PubMed Web of Science ®Google Scholar
• Jin T, Li B, Chen XZ. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res. 2013;21:317–323.
   PubMed Web of Science ®Google Scholar
• Guan Y, Li A, Xiao W, et al. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015;6:33926–33934.
   PubMed Web of Science ®Google Scholar
• Lee SC, Lim SG, Soo R, et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics. 2006;16:73–74.
   PubMed Web of Science ®Google Scholar
• Or YY, Hui AB, To KF, et al. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer. 2006;118:1065–1067.
   PubMed Web of Science ®Google Scholar
• Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Invest New Drugs. 2012;31:567–575.
   PubMed Web of Science ®Google Scholar
• Yang F, Qian XJ, Qin W, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. Plos One. 2013;8:e59879.
   Google Scholar
• Ma BB, Lui VW, Hui EP, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs. 2010;28:413–420.
   PubMed Web of Science ®Google Scholar
• Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014;343:24–32.
   PubMed Web of Science ®Google Scholar
• Ma B, Hui EP, King A, et al. A phase II study of gefitinib in patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 2008;62:59–64.
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568–3576.
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038–2044.
   PubMed Web of Science ®Google Scholar
• Ma BB, Kam MK, Leung SF, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2011;23:1287–1292.
   PubMed Web of Science ®Google Scholar
• Xu T, Liu Y, Dou S, et al. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol. 2015;51:875–879.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–594.
   PubMed Web of Science ®Google Scholar
• Xue C, Tian Y, Zhang J, et al. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Des Devel Ther. 2016;10:1299–1306.
   PubMed Web of Science ®Google Scholar
• Fendri A, Khabir A, Mnejja W, et al. PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci. 2009;100:2034–2039.
   PubMed Web of Science ®Google Scholar
• Ma BB, Goh BC, Lim WT, et al. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the Mayo phase II consortium and the cancer therapeutics research group (MC1079). Invest New Drugs. 2015;33:985–991.
   PubMed Web of Science ®Google Scholar
• Wong CH, Ma BB, Cheong HT, et al. Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma. Am J Cancer Res. 2015;5:1496–1506.
   PubMed Web of Science ®Google Scholar
• Huang A, Frisch C, Wilson C, et al. Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. AACR 2012, Chicago. Cancer Res. 72:abstr 3749.
   Web of Science ®Google Scholar
• Hui AB, Or YY, Takano H, et al. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res. 2005;65:8125–8133.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zeng Z, Zhou Y, et al. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochim Biophys Sin (Shanghai). 2009;41:414–428.
   PubMed Web of Science ®Google Scholar
• Song X, Tao YG, Zeng L, et al. Latent membrane protein 1 encoded by Epstein-Barr virus modulates directly and synchronously cyclin D1 and p16 by newly forming a c-Jun/Jun B heterodimer in nasopharyngeal carcinoma cell line. Virus Res. 2005;113:89–99.
   PubMed Web of Science ®Google Scholar
• Hsieh WS, Soo R, Peh BK, et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res. 2009;15:1435–1442.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748.
   PubMed Web of Science ®Google Scholar
• Ma BB, Wong CH, Hui C, et al. Preclinical evaluation of the CDK4/6 inhibitor LEE011 in nasopharyngeal carcinoma (NPC) cell lines. AACR 2016, New Orleans. Cancer Res. 2016;14(Suppl):abstr 3773.
   Web of Science ®Google Scholar
• Wong JH, Lui VW, Umezawa K, et al. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett. 2010;287:23–32.
   PubMed Web of Science ®Google Scholar
• Hui KF, Lam BH, Ho DN, et al. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther. 2013;12:747–758.
   PubMed Web of Science ®Google Scholar
• Jiang GM, Wang HS, Du J, et al. Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation. Cancer Immunol Res. 2017;5:42–51.
   PubMed Web of Science ®Google Scholar
• Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007;9:1–24.
   PubMedGoogle Scholar
• Chan A, Tao Q, Robertson K, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol. 2004;22:1373–1381.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang X, Zhao M, et al. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014;5:3127.
   PubMed Web of Science ®Google Scholar
• Rotolo F, Pignon JP, Bourhis J, et al. Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. J Natl Cancer Inst. 2017; 109(4). pii: djw239.
   PubMedGoogle Scholar
• Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252–1258.
   PubMed Web of Science ®Google Scholar
• Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008;99:1311–1318.
   PubMed Web of Science ®Google Scholar
• Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101:300–306.
   PubMed Web of Science ®Google Scholar
• Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncol. 2016;62:147–148.
   PubMed Web of Science ®Google Scholar
• Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:1016–1024.
   PubMed Web of Science ®Google Scholar
• Yen TC, Lin CY, Wang HM, et al. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:1307–1314.
   PubMed Web of Science ®Google Scholar
• Ma B, Leung SF, Hui EP, et al. Prospective evaluation of both plasma Epstein Barr Virus (EBV) DNA clearance and fludeoxyglucose-positron emission tomography (PET-CT) as a dual-endpoint in predicting early response and survival of patients undergoing chemotherapy (chemo) for advanced nasopharyngeal carcinoma (NPC) (NCT01365208). European Cancer Congress. 2015;51(Supp 3):abstract 2870.
   Google Scholar
• Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31:1834–1841.
   PubMed Web of Science ®Google Scholar